文献速递临床免疫临床微生物

新型半定量隐球菌抗原侧向流检测在晚期HIV患者中的评估

Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease.
PubMed 文献 · J Clin Microbiol · 2020-08-24

该研究对IMMY半定量隐球菌抗原侧向流检测(CrAgSQ LFA)进行实验室验证,共检测872份血浆样本(692份来自HIV阳性筛查者,180份已知CrAg阳性存档样本)。以IMMY CrAg LFA为参考标准,CrAgSQ灵敏度93.0%、特异度93.8%;经酶免疫检测重新分类不一致结果后,灵敏度98.1%、特异度95.8%。CrAgSQ评分与稀释滴度及10周死亡率强相关。

要点

  • CrAgSQ LFA与常规IMMY CrAg LFA相比具有高灵敏度和特异度。
  • CrAgSQ半定量评分与稀释滴度及10周死亡率强相关。
  • CrAgSQ读数者间一致性极好(Cohen's kappa 0.962)。

核心结论

  • IMMY CrAgSQ检测与IMMY CrAg LFA相比具有高灵敏度和特异度。
  • CrAgSQ评分与常规CrAg滴度和临床结局均相关。

研究设计与样本

  • 实验室验证研究,共检测872份血浆样本,其中692份为HIV阳性筛查者的连续样本,180份为既往研究存档的已知CrAg阳性样本。

主要发现

  • 以IMMY CrAg LFA为参考标准,CrAgSQ灵敏度93.0%(95%CI 80.9%–98.5%),特异度93.8%(95%CI 91.7%–95.6%)。
  • 经CrAg酶免疫检测重新分类不一致结果后,灵敏度98.1%(95%CI 90.1%–100%),特异度95.8%(95%CI 93.9%–97.2%)。
  • CrAgSQ 1+至4+评分对应的中位CrAg滴度分别为1:10(IQR 1:5–1:20)、1:40(IQR 1:20–1:80)、1:640(IQR 1:160–1:2,560)、1:5,120(IQR 1:2,560–1:30,720)。
  • CrAgSQ评分升高与10周死亡率强相关。
  • 读数者间一致性极好(98.17%一致,Cohen's kappa 0.962,P < 0.001)。

关键数值与推荐

  • CrAgSQ半定量评分1+对应中位滴度1:10(IQR 1:5–1:20)。
  • CrAgSQ半定量评分2+对应中位滴度1:40(IQR 1:20–1:80)。
  • CrAgSQ半定量评分3+对应中位滴度1:640(IQR 1:160–1:2,560)。
  • CrAgSQ半定量评分4+对应中位滴度1:5,120(IQR 1:2,560–1:30,720)。

临床怎么用

  • CrAgSQ LFA可用于HIV阳性个体的CrAg筛查,并提供与滴度和预后相关的半定量评分。
  • CrAgSQ评分可能有助于治疗分层,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Higher cryptococcal antigen (CrAg) titers are strongly associated with mortality risk in individuals with HIV-associated cryptococcal disease. Rapid tests to quantify CrAg levels may provide important prognostic information and enable treatment stratification. We performed a laboratory-based validation of the IMMY semiquantitative cryptococcal antigen (CrAgSQ) lateral flow assay (LFA) against the current gold standard CrAg tests. We assessed the diagnostic accuracy of the CrAgSQ in HIV-positive individuals undergoing CrAg screening, determined the relationship between CrAgSQ scores and dilutional CrAg titers, assessed interrater reliability, and determined the clinical correlates of CrAgSQ scores. A total of 872 plasma samples were tested using both the CrAgSQ LFA and the conventional IMMY CrAg LFA, of which 692 were sequential samples from HIV-positive individuals undergoing CrAg screening and an additional 180 were known CrAg-positive plasma samples archived from prior studies. Interrater agreement in CrAgSQ reading was excellent (98.17% agreement, Cohen's kappa 0.962, P < 0.001). Using the IMMY CrAg LFA as a reference standard, CrAgSQ was 93.0% sensitive (95% confidence interval [CI] 80.9% to 98.5%) and 93.8% specific (95% CI, 91.7% to 95.6%). After reclassification of discordant results using CrAg enzyme immunoassay testing, the sensitivity was 98.1% (95% CI, 90.1% to 100%) and specificity 95.8% (95% CI, 93.9% to 97.2%). The median CrAg titers for semiquantitative score categories (1+ to 4+) were 1:10 (interquartile range [IQR], 1:5 to 1:20) in the CrAgSQ 1+ category, 1:40 (IQR, 1:20 to 1:80) in the CrAgSQ 2+ category, 1:640 (IQR, 1:160 to 1:2,560) in the CrAgSQ 3+ category, and 1:5,120 (IQR, 1:2,560 to 1:30,720) in the CrAgSQ 4+ category. Increasing CrAgSQ scores were strongly associated with 10-week mortality. The IMMY CrAgSQ test had high sensitivity and specificity compared to the results for the IMMY CrAg LFA and provided CrAg scores that were associated with both conventional CrAg titers and clinical outcomes.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Jarvis JN, Tenforde MW, Lechiile K, et al. Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. J Clin Microbiol. 2020. PMID: 32461286. doi:10.1128/JCM.00441-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。